Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Francesco Stella
Partner Corporate & Finance
Languages
English, Italian
A passion for complex deals brought him to focus on regulated assets ranging from financial institutions to life science companies and energy businesses. Clients in these industries know they can rely on Francesco's sector knowledge, which is always coupled with his thoroughness, keen eye for detail and commitment to excellence. Francesco has been mentioned in all major legal directories for many years. From time to time, he likes to lecture on cutting-edge subjects at conferences and seminars.
Assistance to BNP Paribas Cardif in the setting up of a life bancassurance partnership with ICCREA, including the acquisition of a majority stake in BCC Vita from ICCREA.
Assistance to BNP Paribas Cardif in the termination of a non-life bancassurance partnership with IntesaSanPaolo, including the sale of 100% of Cargeas Assicurazioni to IntesaSanPaolo.
Assistance to BNL in the setting up of a service payment partnership with Worldline, including the sale of a 80% stake of Axepta to Worldline.
Assistance to CNP in the acquisition of the Italian life business of Aviva, including various legal entities (Aviva Spa, Aviva Life Spa, Aviva Italia Scarl).
Assistance to CNP in the acquisition of a 49% stake in CNP Vita Assicura from UniCredit.
Assistance to Dana in the acquisition of 80% of the global power-transmission and fluid power business of Brevini Group from the Brevini family and subsequent buy-out of minorities.
Assistance to Fagerhult in the acquisition of 100% of iGuzzini Illuminazione fro the Guzzini family.
Assistance to FlixBus on the development of its expansion strategy in Italy, which included several acquisitions (SAPS, Roma Marche Linee, Baltour and others).
Assistance to Recordati in the acquisition of European commercial rights to a portfolio of drugs (“seloken”) from Astra Zeneca.
Assistance to Recordati in the acquisition of worldwide commercial rights to a portfolio of drugs ("signifor" and "osilodrostat") from Novartis.